Differences in CYP2C9 genotype and enzyme activity between Swedes and Koreans of relevance for personalized medicine: Role of ethnicity, genotype, smoking, age, and sex

Title
Differences in CYP2C9 genotype and enzyme activity between Swedes and Koreans of relevance for personalized medicine: Role of ethnicity, genotype, smoking, age, and sex
Authors
강주희
Issue Date
2015-06
Publisher
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
Series/Report no.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY ; Vol19 no.6 Startpage 346 Endpage 353
Abstract
Global personalized medicine demands the characterization of person-to-person and between-population differences in drug pharmacokinetics and pharmacodynamics. CYP2C9 pharmacokinetic pathway is subject to modulation by both genetic and environmental factors. CYP2C9 genotype-based dose recommendations (e.g., for warfarin) is advocated. However, the overall contribution of genotype for variation in enzyme activity may differ between populations. We evaluated the importance of ethnicity, genotype, smoking, body weight, age, and sex for CYP2C9 enzyme activity. CYP2C9 genotype and phenotype was determined in 148 Swedes and 146 Koreans using losartan as a probe. CYP2C9 enzyme activity was assessed using urinary losartan/metabolite E-3174 ratio. The frequency of CYP2C9 defective variant alleles (*2 and *3) was significantly higher in Swedes (10.8% and 12.5%) than in Koreans (0% and 5.8%). In matched genotypes, CYP2C9 enzyme activity was significantly lower in Swedes compared to Koreans (p<0.0001). In a univariate analysis, age, weight, ethnicity, genotype, and smoking were significant predictors of CYP2C9 phenotype. A stepwise multivariate analysis indicated ethnicity, genotype, and smoking remained as significant predictors of CYP2C9 enzyme activity, accounting for 50% of the total variance. In both study populations, CYP2C9 genotype was a significant predictor of CYP2C9 enzyme activity, but its contribution in explaining the total variance was lower in Koreans (26.6%) than Swedes (40%). In conclusion, we report significantly lower CYP2C9 enzyme activity in Swedes compared to Koreans, partly but not exclusively due to CYP2C9 pharmacogenetic variations. Ethnicity and environment factors need to be considered together with genotype for population-specific dose optimization and global personalized medicine.
URI
https://www.liebertpub.com/doi/10.1089/omi.2015.0022
http://dspace.inha.ac.kr/handle/10505/55174
ISSN
1536-2310
Appears in Collections:
Medical School/College of Medicine (의학전문대학원/의과대학) > Medical Science (의학) > Journal Papers, Reports(의학 논문, 보고서)
Files in This Item:
580_Differences in CYP2C9 genotype.pdfDownload

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse